financetom
CYAN
financetom
/
Consumer Staples
/
CYAN
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Cyanotech CorporationCYAN
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide.

The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids.

It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets.

The company was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.

Latest News >
AMC tops revenue target as box office hits drive strong demand
AMC tops revenue target as box office hits drive strong demand
Feb 25, 2025
Feb 25 (Reuters) - AMC Entertainment ( AMC ) topped Wall Street estimates for quarterly revenue on Tuesday, boosted by wildly popular releases including Moana 2 and Wicked that helped draw a strong crowd of moviegoers. Shares of the company rose about 3% in extended trading after it reported a 20% jump in attendance in theaters in the fourth quarter....
Range Resources Q4 Adjusted Earnings Rise, Revenue Declines
Range Resources Q4 Adjusted Earnings Rise, Revenue Declines
Feb 25, 2025
05:15 PM EST, 02/25/2025 (MT Newswires) -- Range Resources ( RRC ) late Tuesday reported Q4 adjusted net income of $0.68 per diluted share, up from $0.63 a year earlier. Analysts polled by FactSet expected $0.61. Revenue for the quarter ended Dec. 31 was $626.4 million, down from $941.5 million a year earlier. Analysts surveyed by FactSet expected $691.1 million....
Vaxcyte 2024 Loss Narrows
Vaxcyte 2024 Loss Narrows
Feb 25, 2025
05:20 PM EST, 02/25/2025 (MT Newswires) -- Vaxcyte ( PCVX ) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier. Analysts polled by FactSet expected a per-share loss of $3.91. The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec....
Boehringer Ingelheim wins trial in two Zantac lawsuits
Boehringer Ingelheim wins trial in two Zantac lawsuits
Feb 25, 2025
Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. A state court jury in Chicago on Monday found in favor of the privately held German drugmaker following a joint trial of individual cases brought by Chicago residents...
Copyright 2023-2026 - www.financetom.com All Rights Reserved